Cargando…
Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy
BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy, improving outcomes in the treatment of various malignancies. However, not all patients benefit to the same extend from ICI. Reliable tools to predict treatment response and outcome are missing. Soluble ur...
Autores principales: | Loosen, Sven H., Gorgulho, Joao, Jördens, Markus S., Schulze-Hagen, Maximilian, Beier, Fabian, Vucur, Mihael, Schneider, Anne T., Koppe, Christiane, Mertens, Alexander, Kather, Jakob N., Tacke, Frank, Keitel, Verena, Brümmendorf, Tim H., Roderburg, Christoph, Luedde, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047604/ https://www.ncbi.nlm.nih.gov/pubmed/33869041 http://dx.doi.org/10.3389/fonc.2021.646883 |
Ejemplares similares
-
Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis
por: Loosen, Sven H, et al.
Publicado: (2021) -
Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
por: Rolles, Benjamin, et al.
Publicado: (2021) -
Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer
por: Loosen, Sven H., et al.
Publicado: (2020) -
Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
por: Loosen, Sven H., et al.
Publicado: (2021) -
Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases
por: Loosen, Sven H., et al.
Publicado: (2018)